138 related articles for article (PubMed ID: 20938222)
1. Role of IGF-I on PTH effects on bone.
Lombardi G; Di Somma C; Vuolo L; Guerra E; Scarano E; Colao A
J Endocrinol Invest; 2010; 33(7 Suppl):22-6. PubMed ID: 20938222
[TBL] [Abstract][Full Text] [Related]
2. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone.
Bikle DD; Sakata T; Leary C; Elalieh H; Ginzinger D; Rosen CJ; Beamer W; Majumdar S; Halloran BP
J Bone Miner Res; 2002 Sep; 17(9):1570-8. PubMed ID: 12211426
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone.
Pfeilschifter J; Laukhuf F; Müller-Beckmann B; Blum WF; Pfister T; Ziegler R
J Clin Invest; 1995 Aug; 96(2):767-74. PubMed ID: 7635970
[TBL] [Abstract][Full Text] [Related]
5. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
Kassem M
APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
[TBL] [Abstract][Full Text] [Related]
6. Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts.
Hilal G; Massicotte F; Martel-Pelletier J; Fernandes JC; Pelletier JP; Lajeunesse D
J Bone Miner Res; 2001 Apr; 16(4):713-21. PubMed ID: 11315999
[TBL] [Abstract][Full Text] [Related]
7. [New drugs with positive effects on bones].
Zofková I; Kanceva RL
Cas Lek Cesk; 1997 Jul; 136(15):459-63. PubMed ID: 9340191
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
[TBL] [Abstract][Full Text] [Related]
9. [Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures].
Kuzma M; Payer J
Cas Lek Cesk; 2010; 149(5):211-6. PubMed ID: 20629339
[TBL] [Abstract][Full Text] [Related]
10. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
[TBL] [Abstract][Full Text] [Related]
11. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism.
Ahmad AM; Thomas J; Clewes A; Hopkins MT; Guzder R; Ibrahim H; Durham BH; Vora JP; Fraser WD
J Clin Endocrinol Metab; 2003 Jun; 88(6):2860-8. PubMed ID: 12788900
[TBL] [Abstract][Full Text] [Related]
12. Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I.
Kostenuik PJ; Harris J; Halloran BP; Turner RT; Morey-Holton ER; Bikle DD
J Bone Miner Res; 1999 Jan; 14(1):21-31. PubMed ID: 9893062
[TBL] [Abstract][Full Text] [Related]
13. Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I.
Staal A; Geertsma-Kleinekoort WM; Van Den Bemd GJ; Buurman CJ; Birkenhäger JC; Pols HA; Van Leeuwen JP
J Bone Miner Res; 1998 Jan; 13(1):36-43. PubMed ID: 9443788
[TBL] [Abstract][Full Text] [Related]
14. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency.
Magnusson P; Degerblad M; Sääf M; Larsson L; Thorén M
J Bone Miner Res; 1997 Feb; 12(2):210-20. PubMed ID: 9041052
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. Somatopause: dismetabolic and bone effects.
Lombardi G; Tauchmanova L; Di Somma C; Musella T; Rota F; Savanelli MC; Colao A
J Endocrinol Invest; 2005; 28(10 Suppl):36-42. PubMed ID: 16550721
[TBL] [Abstract][Full Text] [Related]
17. A transgenic model to determine the physiological role of liver-derived insulin-like growth factor I.
Sjögren K; Jansson JO; Isaksson OG; Ohlsson C
Minerva Endocrinol; 2002 Dec; 27(4):299-311. PubMed ID: 12511852
[TBL] [Abstract][Full Text] [Related]
18. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice.
Yamaguchi M; Ogata N; Shinoda Y; Akune T; Kamekura S; Terauchi Y; Kadowaki T; Hoshi K; Chung UI; Nakamura K; Kawaguchi H
Endocrinology; 2005 Jun; 146(6):2620-8. PubMed ID: 15718274
[TBL] [Abstract][Full Text] [Related]
19. PTH circadian rhythm and PTH target-organ sensitivity is altered in patients with adult growth hormone deficiency with low BMD.
White HD; Ahmad AM; Durham BH; Peter R; Prabhakar VK; Corlett P; Vora JP; Fraser WD
J Bone Miner Res; 2007 Nov; 22(11):1798-807. PubMed ID: 17645402
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.
Aslan D; Andersen MD; Gede LB; de Franca TK; Jørgensen SR; Schwarz P; Jørgensen NR
Scand J Clin Lab Invest; 2012 Feb; 72(1):14-22. PubMed ID: 22085136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
